SELLAS Life Sciences Surges on Phase 3 Cancer Trial Milestone

By EC Assets · Published

Shares of SELLAS Life Sciences Group advanced sharply following clinical updates on its late-stage cancer pipeline. The biopharmaceutical company reported positive topline results from its ongoing trial programme, sending the stock higher by 240% during early trading on Tuesday. The significant price advance followed developments in the clinical progression of galinpepimut-S, the company's candidate being evaluated in oncology treatments. The development programme reached a critical procedural threshold after its Phase 3 REGAL trial accumulated its pre-set 80th event. That milestone formally triggered the final analysis of overall survival outcomes across the patient cohort. Market focus has shifted intensely toward the final survival data following that milestone. The company previously witnessed its stock trace a very steep path over recent years, accompanied by periodic pullbacks that raised questions regarding whether the valuation fully reflected expectations surrounding the Phase 3 trigger. The latest rally arrives against a volatile historical backdrop for SELLAS Life Sciences Group equity. While earlier pullbacks placed a spotlight on the company's valuation metrics, the release of positive topline trial results restored rapid upward momentum. Market participants now await the conclusive overall survival data from the final analysis of the REGAL trial. This article is intended for informational purposes only. It does not constitute investment advice.

Stay informed

Market commentary, firm news and research from EC Assets - direct to your inbox.